Click aici pentru detalii

[211] Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D.
Effect of antiarrhythmic therapy on mortality in survivors of
myocardial infarction with asymptomatic complex ventricular
arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS).
J Am Coll Cardiol 1990; 16: 1711-18.
[212] Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in
patients with congestive heart failure and asymptomatic ventricular
arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive
Heart Failure. N Engl J Med 1995; 333: 77-82.
[213] Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman
GR, Curiel R. Randomised trial of low-dose amiodarone in severe
congestive heart failure. Grupo de Estudio de la Sobrevida en la
Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344:
493-8.
[214] Garguichevich JJ, Ramos JL, Gambarte A et al. Effect of
amiodarone therapy on mortality in patients with left ventricular
dysfunction and asymptomatic complex ventricular arrhythmias:
Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA).
Am Heart J 1995; 130: 494-500.
[215] Hamer AW, Arkles LB, Johns JA. Beneficial effects of low dose
amiodarone in patients with congestive cardiac failure: a placebocontrolled
trial. J Am Coll Cardiol 1989; 14: 1768-74.
[216] Janse MJ, Malik M, Camm AJ, Julian DG, Frangin GA,
Schwartz PJ. Identification of post acute myocardial infarction patients
with potential benefit from prophylactic treatment with amiodarone.
A substudy of EMIAT (the European Myocardial Infarct Amiodarone
Trial). Eur Heart J 1998; 19: 85-95.
[217] Mason JW. A comparison of seven antiarrhythmic drugs in
patients with ventricular tachyarrhythmias. Electrophysiologic Study
versus Electrocardiographic Monitoring Investigators. N Engl J Med
1993; 329: 452-8.
[218] Haverkamp W, Martinez-Rubio A, Hief C et al. Efficacy and
safety of d,l-sotalol in patients with ventricular tachycardia and in
survivors of cardiac arrest. J Am Coll Cardiol 1997; 30: 487-95.
[219] Held PH, Yusuf S, Furberg CD. Calcium channel blockers in
acute myocardial infarction and unstable angina: an overview. BMJ
1989; 299: 1187-92.
[220] Effect of verapamil on mortality and major events after acute
myocardial infarction (the Danish Verapamil Infarction Trial II-
DAVIT II). Am J Cardiol 1990; 66: 779-85.
[221] Waters D, Lesperance J, Francetich M et al. A controlled
clinical trial to assess the effect of a calcium channel blocker on the
progression of coronary atherosclerosis. Circulation 1990; 82: 1940-53.
[222] Yusuf S, Held P, Furberg C. Update of effects of calcium
antagonists in myocardial infarction or angina in light of the second
Danish Verapamil Infarction Trial (DAVIT-II) and other recent
studies. Am J Cardiol 1991; 67: 1295-7.
[223] Mirowski M, Reid PR, Mower MM et al. Termination of
malignant ventricular arrhythmias with an implanted automatic
defibrillator in human beings. N Engl J Med 1980; 303: 322-4.
[224] Fogoros RN, Fiedler SB, Elson JJ. The automatic
implantable cardioverter-defibrillator in drug-refractory ventricular
tachyarrhythmias. Ann Intern Med 1987; 107: 635-41.
[225] Winkle RA, Mead RH, RuderMA et al. Long-term outcome
with the automatic implantable cardioverter-defibrillator. J Am Coll
Cardiol 1989; 13: 1353-61.
[226] Fogoros RN, Elson JJ, Bonnet CA, Fiedler SB, Burkholder JA.
Efficacy of the automatic implantable cardioverter defibrillator in
prolonging survival in patients with severe underlying cardiac disease.
J Am Coll Cardiol 1990; 16: 381-6.
[227] Levine JH, Mellits ED, Baumgardner RA et al. Predictors of
first discharge and subsequent survival in patients with automatic
implantable cardioverter-defibrillators. Circulation 1991; 84: 558-66.
[228] de Marchena E, Chakko S, Fernandez P et al. Usefulness of the
automatic implantable cardioverter defibrillator in improving survival
of patients with severely depressed left ventricular function associated
66
with coronary artery disease. Am J Cardiol 1991; 67: 812-816.
[229] Newman D, Sauve MJ, Herre J et al. Survival after
implantation of the cardioverter defibrillator. Am J Cardiol 1992; 69:
899-903.
[230] Bardy GH, Hofer B, Johnson G et al. Implantable transvenous
cardioverter-defibrillators. Circulation 1993; 87:1152-68.
[231] Moss AJ, Hall WJ, Cannom DS et al. Improved survival with
an implanted defibrillator in patients with coronary disease at high risk
for ventricular arrhythmia. Multicenter Automatic Defibrillator
Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-40.
[232] Bigger JT, Jr. Prophylactic use of implanted cardiac
defibrillators in patients at high risk for ventricular arrhythmias after
coronary-artery bypass graft surgery. Coronary Artery Bypass Graft
(CABG) Patch Trial Investigators. N Engl J Med 1997; 337: 1569-75.
[233] Denes P, Gillis AM, Pawitan Y, Kammerling JM, Wilhelmsen
L, Salerno DM. Prevalence, characteristics and significance of
ventricular premature complexes and ventricular tachycardia detected
by 24-hour continuous electrocardiographic recording in the Cardiac
Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol
1991; 68: 887-96.
[234] Buxton AE, Marchlinski FE, Flores BT, Miller JM, Doherty
JU, Josephson ME. Nonsustained ventricular tachycardia in patients
with coronary artery disease: role of electrophysiologic study.
Circulation 1987; 75: 1178-85.
[235] Wilber DJ, Olshansky B, Moran JF, Scanlon PJ.
Electrophysiological testing and nonsustained ventricular tachycardia.
Use and limitations in patients with coronary artery disease and
impaired ventricular function. Circulation 1990; 82: 350-8.
[236] Kleiger RE, Miller JP, Bigger JT, Jr, Moss AJ. Decreased heart
rate variability and its association with increased mortality after acute
myocardial infarction. Am J Cardiol 1987; 59: 256-62.
[237] La Rovere MT, Specchia G, Mortara A, Schwartz PJ.
Baroreflex sensitivity, clinical correlates, and cardiovascular mortality
among patients with a first myocardial infarction. A prospective study.
Circulation 1988; 78: 816-24.
[238] Bocker D, Haverkamp W, Block M, Borggrefe M, Hammel
D, Breithardt G. Comparison of d,l-sotalol and implantable
defibrillators for treatment of sustained ventricular tachycardia or
fibrillation in patients with coronary artery disease. Circulation 1996;
94: 151-7.
[239] Randomized antiarrhythmic drug therapy in survivors of
cardiac arrest (the CASCADE Study). The CASCADE Investigators.
Am J Cardiol 1993; 72: 280-7.
[240] A comparison of antiarrhythmic-drug therapy with implantable
defibrillators in patients resuscitated from near-fatal ventricular
arrhythmias. The Antiarrhythmics versus Implantable Defibrillators
(AVID) Investigators. N Engl J Med 1997; 337: 1576-83.
[241] Connolly SJ, Gent M, Roberts RS et al. Canadian implantable
defibrillator study (CIDS): a randomized trial of the implantable
cardioverter defibrillator against amiodarone. Circulation 2000; 101:
1297-1302.
[242] Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized
comparison of antiarrhythmic drug therapy with implantable
defibrillators in patients resuscitated from cardiac arrest: the Cardiac
Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-54.
[243] Connolly SJ, Hallstrom AP, Cappato R et al. Meta-analysis of
the implantable cardioverter defibrillator secondary prevention trials.
Eur Heart J 2000; 21: 2071-8.
[244] Morady F, Harvey M, Kalbfleisch SJ, el Atassi R, Calkins H,
Langberg JJ. Radiofrequency catheter ablation of ventricular
tachycardia in patients with coronary artery disease. Circulation 1993;
87: 363-72.
[245] Stevenson WG, Khan H, Sager P et al. Identification of
reentry circuit sites during catheter mapping and radiofrequency
ablation of ventricular tachycardia late after myocardial infarction.
Circulation 1993; 88: 1647-70.
REVISTA ROMÅN~ DE CARDIOLOGIE Vol. XIX, Nr. 1, An 2004